Bicara Therapeutics Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCAX research report →
Range $8 – $41
Price Chart
About the company
Bicara Therapeutics Inc. , a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors.
- CEO
- Claire Mazumdar Clemon
- IPO
- 2024
- Employees
- 103
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on BCAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $560.31M
- P/E
- -2.70
- Fwd P/E
- 11.90
- PEG
- 0.07
- P/S
- 0.00
- P/B
- 1.57
- EV/EBITDA
- -2.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -49.13%
- ROIC
- -57.77%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-155,604,000
- Net Income
- $-137,950,000-102.9%
- EPS
- $-2.52-101.6%
- OCF Growth
- -42.9%
- FCF Growth
- -43.2%
- 52W High
- $30.99
- 52W Low
- $7.87
- 50D MA
- $15.72
- 200D MA
- $20.69
- Beta
- -0.82
- RSI (14)
- 28
- Avg Volume
- 1.20M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bicara said FORTIFI-HN01 has reached substantial enrollment, expects interim top-line data in mid-2027, and is adding an interim overall survival readout as it positions FICERA for a competitive launch in HPV-negative head and neck cancer.· November 9, 2026
- FORTIFI-HN01 hit substantial enrollment, keeping the company on track for an interim top-line analysis in the middle of next year.
- Management said it will incorporate an interim overall survival analysis, but timing and scope were not yet disclosed.
- The company highlighted Phase Ib data for FICERA plus pembrolizumab showing a 54% confirmed objective response rate, 25% complete response rate, and nearly 22-month median duration of response.
- Cash and investments were approximately $442.3 million at quarter-end, with runway into the first half of 2029.
- R&D and G&A spending increased year over year as Bicara expands the pivotal program and builds toward commercialization.
Bicara did not report revenue or EPS on the call. Research and development expenses were $56.5 million in the third quarter of 2026 versus $33 million in the third quarter of 2025, while general and administrative expenses were $19.2 million versus $7.7 million a year earlier. The company ended the third quarter of 2026 with approximately $442.3 million in cash, cash equivalents and marketable securities, which it said provides runway into the first half of 2029. Management said overall operating expenses through year-end are expected to remain consistent with the most recent quarterly results. On guidance, the company expects the FORTIFI-HN01 interim top-line analysis in the middle of next year, plans to include an interim OS analysis, expects FORTIFI-FLEX data before the first approval, and said the CRC expansion data will be presented in January.
Ryan Cohlhepp framed FICERA as a differentiated, practice-changing program for frontline recurrent metastatic HPV-negative head and neck cancer and said the company’s conversations with clinicians reinforce confidence in the drug’s depth and durability of response, chemo-sparing potential, and possible future every-3-week dosing. He emphasized that FORTIFI-HN01’s substantial enrollment and the planned interim OS analysis are important steps toward a BLA that balances speed to market with a competitive label. His tone was confident but careful, repeatedly stressing execution, regulatory engagement, and the need to adapt to a fluid and increasingly competitive landscape.
Jennifer Larson said third-quarter R&D rose to $56.5 million from $33 million a year ago, mainly due to FORTIFI-HN01, FORTIFI-FLEX, Phase I/Ib dose expansion work, and higher personnel costs. G&A increased to $19.2 million from $7.7 million, reflecting added headcount and professional fees as the company prepares for potential commercialization. She said operating expenses should remain consistent with the most recent quarterly level through year-end. She also said Bicara ended the quarter with about $442.3 million in cash, cash equivalents and marketable securities, supporting runway into the first half of 2029, including funding for the pivotal study, interim OS work, launch preparations, FORTIFI-FLEX, manufacturing, and other corporate purposes.
Analysts focused on why HPV status matters so much, and management said the biology and historical EGFR data show clear differences between HPV-positive and HPV-negative disease, which is why FORTIFI-HN01 enrolls only HPV-negative patients. They also asked about the new interim OS analysis; Ryan Cohlhepp said the company is confident in the current trial size of around 650 patients and does not expect to upsize the study, but did not give timing. Questions on competitive pressure centered on recent head and neck data and amivantamab; management said off-label use appears limited, the trial is blinded, and post-discontinuation therapy effects will be analyzed. On the commercial side, management said petosemtamab is an important competitor, but Bicara still expects to compete on depth, durability, and ultimately overall survival, with pricing tied to the value FICERA brings.
The call reinforced a strong clinical narrative: Phase Ib data showed a 54% ORR, 25% CR rate, nearly 22-month median duration of response, and median OS just over 21 months in a hard-to-treat HPV-negative population. Management believes the blinded pivotal study is now well positioned, enrollment momentum is strong, and the company has enough cash to fund operations well into 2029. They also described a potentially differentiated commercial profile built around chemo-sparing treatment, flexibility in dosing, and a possible OS-inclusive label.
Bicara is still waiting on pivotal data, and the company acknowledged that the competitive environment is evolving quickly with new readouts and a more crowded first-line head and neck landscape. Management would not give timing for the interim OS analysis or spell out the regulatory path, which leaves uncertainty around label strategy and launch timing. Spending is rising materially as the company advances the pivotal trial and builds a commercial organization, so execution risk remains high until the data are read out.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 56.1%
- Shares Outstanding
- 66.39M
- Float Shares
- 37.21M
of shares held by institutions
184 13F filers
Buy/sell ratio 0.45. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 7.26M | 0 |
| T. Rowe Price Investment Management, Inc. | 6.34M | ▼ 267.29K |
| Siren, L.L.C. | 5.50M | ▼ 100.00K |
| Vestal Point Capital, LP | 5.25M | ▼ 175.00K |
| Deep Track Capital, LP | 4.10M | ▲ 37.50K |
| Blackrock, Inc. | 3.95M | ▲ 97.40K |
| Janus Henderson Group Ltd. | 3.34M | ▲ 692.93K |
| Jupiter Topco LLC | 3.17M | ▲ 3.17M |
| Tpg Gp A, LLC | 3.01M | 0 |
| Red Tree Management, LLC | 2.92M | ▼ 243.01K |
| Franklin Templeton Inc | 2.67M | ▲ 713.25K |
| Vanguard Capital Management LLC | 2.21M | ▼ 3.15K |
Held by 223 ETFs
Biggest fund positions in BCAX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 26 | Cohlhepp Ryan | other | 17,500 |
| Sep 8, 26 | Cohlhepp Ryan | sell | 14,058 |
| Sep 8, 26 | Cohlhepp Ryan | sell | 3,442 |
| Sep 8, 26 | Cohlhepp Ryan | other | 17,500 |
| Aug 12, 26 | Larson Jennifer | other | 285,000 |
| Aug 12, 26 | Larson Jennifer | other | 0 |
| Aug 10, 26 | Hyep Ivan | other | 12,500 |
| Aug 10, 26 | Hyep Ivan | sell | 12,500 |
| Aug 10, 26 | Hyep Ivan | other | 12,500 |
| Aug 10, 26 | Mazumdar Claire | other | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BCAX coverage
Recent articles, reports, and earnings notes.
No research on BCAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCAX report →Bicara Therapeutics Inc. (BCAX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 9
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 4
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
globenewswire.com · Nov 2
Bicara Therapeutics (NASDAQ:BCAX) Given Buy Rating at BTIG Research
defenseworld.net · Oct 19
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 5
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.